Warning: The NCBI web site requires JavaScript to function. more...
Proteinases in the joint: clinical relevance of proteinases in joint destruction.
Rengel Y, Ospelt C, Gay S.
Arthritis Res Ther. 2007;9(5):221. Review.
Related citations
The clinical potential of matrix metalloproteinase inhibitors in the rheumatic disorders.
Elliott S, Cawston T.
Drugs Aging. 2001;18(2):87-99. Review.
Understanding the role of tissue degrading enzymes and their inhibitors in development and disease.
Cawston TE, Wilson AJ.
Best Pract Res Clin Rheumatol. 2006 Oct;20(5):983-1002. Review.
Matrix metalloproteinase knockout studies and the potential use of matrix metalloproteinase inhibitors in the rheumatic diseases.
Milner JM, Cawston TE.
Curr Drug Targets Inflamm Allergy. 2005 Jun;4(3):363-75. Review.
Joint diseases and matrix metalloproteinases: a role for MMP-13.
Takaishi H, Kimura T, Dalal S, Okada Y, D'Armiento J.
Curr Pharm Biotechnol. 2008 Feb;9(1):47-54. Review.
Reappraising metalloproteinases in rheumatoid arthritis and osteoarthritis: destruction or repair?
Murphy G, Nagase H.
Nat Clin Pract Rheumatol. 2008 Mar;4(3):128-35. Review.
[Cartilage degradation in rheumatoid arthritis].
Ishiguro N.
Clin Calcium. 2009 Mar;19(3):347-54. Review. Japanese.
Metalloproteinase inhibitors and the prevention of connective tissue breakdown.
Cawston TE.
Pharmacol Ther. 1996;70(3):163-82. Review.
Basic calcium phosphate crystals: pathways to joint degeneration.
Molloy ES, McCarthy GM.
Curr Opin Rheumatol. 2006 Mar;18(2):187-92. Review.
Proteinases and inhibitors.
Br Med Bull. 1995 Apr;51(2):385-401. Review.
Cathepsin K deficiency partially inhibits, but does not prevent, bone destruction in human tumor necrosis factor-transgenic mice.
Schurigt U, Hummel KM, Petrow PK, Gajda M, Stöckigt R, Middel P, Zwerina J, Janik T, Bernhardt R, Schüler S, Scharnweber D, Beckmann F, Saftig P, Kollias G, Schett G, Wiederanders B, Bräuer R.
Arthritis Rheum. 2008 Feb;58(2):422-34.
[Bone and bone related biochemical examinations. Bone and collagen related metabolites. Biomarkers for cartilage matrix turnover and destruction in joint diseases].
Kojima T.
Clin Calcium. 2006 Jun;16(6):1009-15. Review. Japanese.
The combination of the biomarkers urinary C-terminal telopeptide of type II collagen, serum cartilage oligomeric matrix protein, and serum chondroitin sulfate 846 reflects cartilage damage in hemophilic arthropathy.
Jansen NW, Roosendaal G, Lundin B, Heijnen L, Mauser-Bunschoten E, Bijlsma JW, Theobald M, Lafeber FP.
Arthritis Rheum. 2009 Jan;60(1):290-8.
The role of proteases in pathologies of the synovial joint.
Jones GC, Riley GP, Buttle DJ.
Int J Biochem Cell Biol. 2008;40(6-7):1199-218. Epub 2008 Feb 1. Review.
The paradox of matrix metalloproteinases in infectious disease.
Elkington PT, O'Kane CM, Friedland JS.
Clin Exp Immunol. 2005 Oct;142(1):12-20. Review.
Scavenger receptor class A type I/II determines matrix metalloproteinase-mediated cartilage destruction and chondrocyte death in antigen-induced arthritis.
van Lent PL, Hofkens W, Blom AB, Grevers L, Sloetjes A, Takahashi N, van Tits LJ, Vogl T, Roth J, de Winther MP, van den Berg WB.
Arthritis Rheum. 2009 Oct;60(10):2954-65.
Myeloid-related proteins S100A8/S100A9 regulate joint inflammation and cartilage destruction during antigen-induced arthritis.
van Lent PL, Grevers L, Blom AB, Sloetjes A, Mort JS, Vogl T, Nacken W, van den Berg WB, Roth J.
Ann Rheum Dis. 2008 Dec;67(12):1750-8. Epub 2007 Nov 30.
Immunological aspects of markers of joint disease.
Caterson B.
J Rheumatol Suppl. 1991 Feb;27:19-23. Review.
Bone morphogenetic proteins in destructive and remodeling arthritis.
Lories RJ, Luyten FP.
Arthritis Res Ther. 2007;9(2):207. Review.
Human bone disorders: pathological role and diagnostic potential of matrix metalloproteinases.
Galliera E, Banfi G, Corsi MM.
Int J Biochem Cell Biol. 2010 Oct;42(10):1590-3. Epub 2010 Jun 25. Review.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on